Table 1.

Currently reported TCR gene transfer attempts for hematological malignancies.

Target antigen	HLA restriction	vector	Comments	Transduction efficacy	Reference
WT1	HLA-A*0201	retroviral vector	WT1-specific TCR gene was transduced into PBL. CD8+ or CD4+ T cells could exert target specificity.	40~60% in total T cells by Vb2 Ab after 2 rounds of antigen-specific stimulation	[8]
	HLA-A*0201	optimized retroviral vector	WT1-specific TCR gene was modified to express more efficiently (hybrid human-murine TCR, Cys-mutant TCR). Patients' PBL transduced WT1-specific TCR could reject the engraftment of autologous CML-BC cells in NOD/SCID mice model.	conventional vector: 0.6% in total CD8+ T cells by tetramer (nonstimulated) optimised vector: 6% in total CD8+ T cells by tetramer (nonstimulated)	[26, 27]
	HLA-A*2402	lentiviral vector	WT1-specific TCR gene was transduced into PBL. CD8+ or CD4+ T cells could exert target specificity in an HLA class I-restricted fashion.	60% in total T cells by Vb5.1 Ab (nonstimulated) 20% in sorted CD8+ T cells by tetramer	[11]
	HLA-A*2402	optimized retroviral vector	The vector could suppress endogenous TCR by shRNA and increase transduced codon-optimized TCR simultaneously.	44% in transduced CD8+ T cells by tetramer	[28]
HA-1	HLA-A*0201	retroviral vector	HA-1-specific TCR gene was transduced into T cells. These transfectants could exert target specificity.	6.6% in transduced T cells by tetrameter	[9]
HA-2	HLA-A*0201	retroviral vector	HA-2-specific TCR gene transduced CD8+ T cell clone was established. These transfectants could exert target specificity.	NA	[10]
	HLA-A*0201	retroviral vector	HA-2-specific TCR gene was transduced into CMV-specific CTL clone to exploit the viral specific response in vivo for the long-term persistence of target TCR transfectants.	NA	[29]

Abbreviations: WT1, Wilms' tumor gene product 1; PBL, peripheral blood lymphocytes; CML-BC, chronic myelogenous leukemia-blastic crisis; CMV, cytomegalovirus; NA, not available; Ab, antibody.